Science
One molecule, three anti-inflammatory targets
How Triple Target Activation works, in-silico design and the organ-on-chip platform.
How Triple Target Activation (TTA) works
Most existing anti-inflammatory drugs block a single target, often after inflammation has already become active. Our approach is upstream. We call it TTA — triple-target activation — because each molecule is designed to gently support three interconnected cellular control systems rather than acting on only one. These systems govern how cells use energy, how strongly they mount inflammatory responses, and how well they defend themselves against oxidative damage. By supporting them together, TTA molecules aim to restore cellular resilience.
Scientific evidence suggests direct cross-talk among three targets that often regulate overlapping cellular processes. This indicates that activating one pathway can potentiate the effects of another, leading to a more comprehensive and potent therapeutic outcome than single-target approaches. Their combined activation could lead to enhanced therapeutic effects and holds significant synergy potential — not merely additive — particularly in addressing metabolic disorders, oxidative stress and inflammation.
In particular, TTA should simultaneously lower oxidative stress, reprogram macrophage and inflammatory tone, and improve barrier and metabolic resilience, rather than only suppressing pro-inflammatory cytokines.
Mechanism
From compound to barrier repair
TTA compounds enter the intestinal epithelial cell, activate three cross-talking targets and trigger an early gene-program response that suppresses cytokines, raises IL-10 and repairs the epithelial barrier.
In-silico discovery
AI/ML-assisted in-silico design
Our in-silico pipeline takes natural-substance templates all the way to candidates for synthesis: pharmacophore modelling, machine-learning hit optimisation and hit-to-lead prioritisation by docking, generative design and molecular dynamics.
- AI-assisted scaffold hopping
- Hit discovery
- Pharmacophore ML modelling
- Structure ML modelling
- Virtual library building
- Molecular docking
- Generative AI molecule binding
- Integrated ML filtering
- Molecular dynamics
Balto (Deep Origin) is used for data validation.
Near future: biomarker-driven development with organ-on-chip technology for NAM modelling
P3T’s biomarker-driven preclinical and clinical development process will use “organ-on-chip” technology. The platform simulates human tissue behaviour, allowing highly accurate testing of our SCMs and optimisation of treatment strategies for better efficacy and safety across the stages of drug development.
With the GATEWAY consortium we have applied to EUROSTARS 4 for a 2D and 3D humanised gut-entheseal organ-on-chip platform (project 12259-GATEWAY). If funded, it will be used to study mechanism of action (MoA), pharmacokinetics (PK) and pharmacodynamics (PD) of our SCMs, and for compound biomarker development.
Along the same NAM line, we have also applied to the EIC Pathfinder Challenges 2026 with the TTA-AGE proposal, which fits the same organ-on-chip approach. Both the EUROSTARS 4 and the Pathfinder applications are pending.
Investors
Ready to invest?
P3T is raising a €1M seed round to biological proof of concept. Download the pitch deck or get in touch.